CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

FDA Biologics (BLA & Biosimilars)
Original article

Public Meeting on the Reauthorization of the Biosimilar User Fee Act (BsUFA) - 10/26/2026

RegulatoryNeutral
AI Analysis

Summary

FDA is holding a public meeting on October 26, 2026 regarding the reauthorization of the Biosimilar User Fee Act (BsUFA), a routine regulatory proceeding.

Importance:3/10
Sentiment:
0.00
BsUFABiosimilarUser FeeReauthorizationFDAPublic Meeting

Read the original article

Published by FDA Biologics (BLA & Biosimilars) on September 25, 2026 5:41 PM

Read Original